The proposed bill amends the Arizona Revised Statutes to enhance the accountability and oversight of the Arizona State Board of Pharmacy. Key changes include a requirement for permittees and licensees to notify the board in writing within fifteen business days of any disciplinary actions taken against their permits or licenses in other jurisdictions, as well as reporting any findings related to patient harm from compounded medications. Additionally, permittees must maintain their hours of operation as submitted to the board and notify the board of any unexpected closures lasting five days or more. The board is also granted the authority to issue subpoenas for investigations and delegate certain powers to the executive director.

In terms of prescription drug and controlled substance regulations, the bill removes outdated compliance language and introduces new requirements for wholesalers and distributors to hold valid permits. It clarifies the responsibilities of manufacturers and distributors in providing accurate information to medical practitioners and expands the definition of prescription drugs. The bill also enhances tracking and reporting requirements for controlled substances, requiring medical practitioners to obtain patient utilization reports before prescribing certain medications and mandating dispensers to report prescription information within one business day. The new regulations are set to take effect on March 31, 2025.

Statutes affected:
Introduced Version: 32-1901.01, 32-1904, 32-1925, 32-1926, 32-1926.01, 32-1927, 32-1927.01, 32-1927.02, 32-1930, 32-1941, 32-1965, 36-2602, 36-2604, 36-2606, 36-2608, 13-3451, 32-1963.01, 32-1936, 32-1937, 32-1968, 41-1831, 36-781, 36-661, 15-157, 36-2226.01, 36-3601, 36-2228, 36-2266, 32-1994, 41-1758.03, 13-3401, 41-1061, 41-1091, 32-4301, 36-2501, 91-513, 36-2610, 12-2293, 23-1026, 11-593, 36-198, 36-2901, 11-594, 20-3151